1
|
Wainwright C, Fuller S, Dickinson V, Greenwood W. Fingolimod: Assay analysis of US generic capsule products reveals variation in fingolimod content beyond the recommended acceptance criteria. Mult Scler Relat Disord 2023; 80:105077. [PMID: 37864877 DOI: 10.1016/j.msard.2023.105077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2023] [Accepted: 10/13/2023] [Indexed: 10/23/2023]
Abstract
The immunomodulating agent fingolimod is a sphingosine-1-phosphate receptor modulator used in the treatment of multiple sclerosis (MS). We analyzed three FDA approved fingolimod 0.5 mg generic capsule products for fingolimod content. Assay results demonstrated a wide variation in fingolimod content between manufacturers, with one product demonstrating a fingolimod content of 76.8 % of the approved dose. This falls significantly below the FDA acceptance criteria of 90.0-110.0 % of label claim.
Collapse
Affiliation(s)
- Catherine Wainwright
- Cycle Pharmaceuticals Ltd, The Broers Building, 21JJ Thomson Avenue, Cambridge CB3 0FA, UK.
| | - Steve Fuller
- Cycle Pharmaceuticals Ltd, The Broers Building, 21JJ Thomson Avenue, Cambridge CB3 0FA, UK
| | - Victoria Dickinson
- Cycle Pharmaceuticals Ltd, The Broers Building, 21JJ Thomson Avenue, Cambridge CB3 0FA, UK
| | - Wendy Greenwood
- Cycle Pharmaceuticals Ltd, The Broers Building, 21JJ Thomson Avenue, Cambridge CB3 0FA, UK
| |
Collapse
|
2
|
Al-Kuraishy HM, Batiha GES, Al-Gareeb AI, Al-Harcan NAH, Welson NN. Receptor-dependent effects of sphingosine-1-phosphate (S1P) in COVID-19: the black side of the moon. Mol Cell Biochem 2023; 478:2271-2279. [PMID: 36652045 PMCID: PMC9848039 DOI: 10.1007/s11010-023-04658-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Accepted: 01/02/2023] [Indexed: 01/19/2023]
Abstract
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection leads to hyper-inflammation and amplified immune response in severe cases that may progress to cytokine storm and multi-organ injuries like acute respiratory distress syndrome and acute lung injury. In addition to pro-inflammatory cytokines, different mediators are involved in SARS-CoV-2 pathogenesis and infection, such as sphingosine-1-phosphate (S1P). S1P is a bioactive lipid found at a high level in plasma, and it is synthesized from sphingomyelin by the action of sphingosine kinase. It is involved in inflammation, immunity, angiogenesis, vascular permeability, and lymphocyte trafficking through G-protein coupled S1P receptors. Reduction of the circulating S1P level correlates with COVID-19 severity. S1P binding to sphingosine-1-phosphate receptor 1 (S1PR1) elicits endothelial protection and anti-inflammatory effects during SARS-CoV-2 infection, by limiting excessive INF-α response and hindering mitogen-activated protein kinase and nuclear factor kappa B action. However, binding to S1PR2 opposes the effect of S1PR1 with vascular inflammation, endothelial permeability, and dysfunction as the concomitant outcome. This binding also promotes nod-like receptor pyrin 3 (NLRP3) inflammasome activation, causing liver inflammation and fibrogenesis. Thus, higher expression of macrophage S1PR2 contributes to the activation of the NLRP3 inflammasome and the release of pro-inflammatory cytokines. In conclusion, S1PR1 agonists and S1PR2 antagonists might effectively manage COVID-19 and its severe effects. Further studies are recommended to elucidate the potential conflict in the effects of S1P in COVID-19.
Collapse
Affiliation(s)
- Hayder M Al-Kuraishy
- Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
| | - Gaber El-Saber Batiha
- Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, 22511, AlBeheira, Egypt
| | - Ali I Al-Gareeb
- Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
| | - Nasser A Hadi Al-Harcan
- Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Rasheed University College, Baghdad, Iraq
| | - Nermeen N Welson
- Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Beni-Suef University, Beni-Suef, 62511, Egypt.
| |
Collapse
|
3
|
Lyssy F, Guettler J, Brugger BA, Stern C, Forstner D, Nonn O, Fischer C, Herse F, Wernitznig S, Hirschmugl B, Wadsack C, Gauster M. Platelet-derived factors dysregulate placental sphingosine-1-phosphate receptor 2 in human trophoblasts. Reprod Biomed Online 2023; 47:103215. [PMID: 37301709 DOI: 10.1016/j.rbmo.2023.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Revised: 03/22/2023] [Accepted: 04/11/2023] [Indexed: 06/12/2023]
Abstract
RESEARCH QUESTION Sphingosine-1-phosphate (S1P) is an essential and bioactive sphingolipid with various functions, which acts through five different G-protein-coupled receptors (S1PR1-5). What is the localization of S1PR1-S1PR3 in the human placenta and what is the effect of different flow rates, various oxygen concentrations and platelet-derived factors on the expression profile of S1PR in trophoblasts? DESIGN Expression dynamics of placental S1PR1-S1PR3 were determined in human first trimester (n = 10), pre-term (n = 9) and term (n = 10) cases. Furthermore, the study investigated the expression of these receptors in different primary cell types isolated from human placenta, verified the findings with publicly available single-cell RNA-Seq data from first trimester and immunostaining of human first trimester and term placentas. The study also tested whether the placental S1PR subtypes are dysregulated in differentiated BeWo cells under different flow rates, different oxygen concentrations or in the presence of platelet-derived factors. RESULTS Quantitative polymerase chain reaction revealed that S1PR2 is the predominant placental S1PR in the first trimester and reduces towards term (P < 0.0001). S1PR1 and S1PR3 increased from first trimester towards term (P < 0.0001). S1PR1 was localized in endothelial cells, whereas S1PR2 and S1PR3 were predominantly found in villous trophoblasts. Furthermore, S1PR2 was found to be significantly down-regulated in BeWo cells when co-incubated with platelet-derived factors (P = 0.0055). CONCLUSION This study suggests that the placental S1PR repertoire is differentially expressed across gestation. S1PR2 expression in villous trophoblasts is negatively influenced by platelet-derived factors, which could contribute to down-regulation of placental S1PR2 over time of gestation as platelet presence and activation in the intervillous space increases from the middle of the first trimester onwards.
Collapse
Affiliation(s)
- Freya Lyssy
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Austria
| | - Jacqueline Guettler
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Austria.
| | - Beatrice A Brugger
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Austria
| | - Christina Stern
- Department of Obstetrics and Gynaecology, Medical University of Graz, Austria
| | - Désirée Forstner
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Austria
| | - Olivia Nonn
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Austria; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Experimental Clinical Research Centre, Max Delbrueck Center for Molecular Medicine in the Helmholtz Association and Charité Berlin, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Cornelius Fischer
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany; Institute for Medical Systems Biology (BIMSB), Berlin, Germany
| | - Florian Herse
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Stefan Wernitznig
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Austria
| | - Birgit Hirschmugl
- Department of Obstetrics and Gynaecology, Medical University of Graz, Austria
| | - Christian Wadsack
- Department of Obstetrics and Gynaecology, Medical University of Graz, Austria
| | - Martin Gauster
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Austria
| |
Collapse
|
4
|
Wang N, Li JY, Zeng B, Chen GL. Sphingosine-1-Phosphate Signaling in Cardiovascular Diseases. Biomolecules 2023; 13:biom13050818. [PMID: 37238688 DOI: 10.3390/biom13050818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 05/07/2023] [Accepted: 05/10/2023] [Indexed: 05/28/2023] Open
Abstract
Sphingosine-1-phosphate (S1P) is an important sphingolipid molecule involved in regulating cardiovascular functions in physiological and pathological conditions by binding and activating the three G protein-coupled receptors (S1PR1, S1PR2, and S1PR3) expressed in endothelial and smooth muscle cells, as well as cardiomyocytes and fibroblasts. It exerts its actions through various downstream signaling pathways mediating cell proliferation, migration, differentiation, and apoptosis. S1P is essential for the development of the cardiovascular system, and abnormal S1P content in the circulation is involved in the pathogenesis of cardiovascular disorders. This article reviews the effects of S1P on cardiovascular function and signaling mechanisms in different cell types in the heart and blood vessels under diseased conditions. Finally, we look forward to more clinical findings with approved S1PR modulators and the development of S1P-based therapies for cardiovascular diseases.
Collapse
Affiliation(s)
- Na Wang
- Key Laboratory of Medical Electrophysiology, Ministry of Education & Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou 646000, China
| | - Jing-Yi Li
- Key Laboratory of Medical Electrophysiology, Ministry of Education & Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou 646000, China
| | - Bo Zeng
- Key Laboratory of Medical Electrophysiology, Ministry of Education & Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou 646000, China
| | - Gui-Lan Chen
- Key Laboratory of Medical Electrophysiology, Ministry of Education & Medical Electrophysiological Key Laboratory of Sichuan Province, Institute of Cardiovascular Research, Southwest Medical University, Luzhou 646000, China
| |
Collapse
|
5
|
Dertschnig S, Passweg J, Bucher C, Medinger M, Tzankov A. Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation. Cell Immunol 2023; 388-389:104719. [PMID: 37141843 DOI: 10.1016/j.cellimm.2023.104719] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 03/27/2023] [Accepted: 04/21/2023] [Indexed: 05/06/2023]
Abstract
Graft-versus-leukemia (GvL) effects are critical to prevent relapses after allogeneic hematopoietic cell transplantation (allo-HCT). However, the success of allo-HCT is limited by graft-versus-host disease (GvHD). Both, CD4+ and CD8+ T cells contribute to GvHD and GvL. The sphingosine-1-phosphate receptor (S1PR) signaling plays a crucial role in lymphocyte trafficking. Mocravimod is an S1PR modulator and its administration leads to blocking lymphocyte egress from lymphoid organs. We hypothesized that this applies to the bone marrow (BM) too, and analyzed BM biopsies from the clinical study with mocravimod (phase I trial in allo-HCT patients; NCT01830010) by immunohistochemical staining for CD3, CD4, CD8, TIA1, FoxP3, PD1, T-Bet, GATA3, and ROR-γt to identify and quantify T cell subsets in situ. Allo-HCT patients without receiving mocravimod were used as controls. BM from 9 patients in the mocravimod group and 10 patients in the control group were examined. CD3+ T cells were found to accumulate in the BM of mocravimod-treated patients compared to controls, both on day 30 and 90 post-transplant. The effect was stronger for CD4+ T cells, than CD8+ T cells, which is in line with data from murine studies showing that CD4+ T cells are more sensitive to mocravimod treatment than CD8+ T cells. Clinically-relevant acute GvHD events (grade II-IV) were slightly lower, but comparable to controls when mocravimod was administered. Taken together, data are supportive of mocravimod's mode of action and bring additional evidence of fewer relapses for allo-HCT patients treated with S1PR modulators.
Collapse
Affiliation(s)
| | - Jakob Passweg
- Hematology, University Hospital Basel, Basel, Switzerland
| | | | | | - Alexandar Tzankov
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
| |
Collapse
|
6
|
Leßmann V, Kartalou GI, Endres T, Pawlitzki M, Gottmann K. Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD? J Neural Transm (Vienna) 2023:10.1007/s00702-023-02618-5. [PMID: 37014414 PMCID: PMC10374694 DOI: 10.1007/s00702-023-02618-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Accepted: 03/02/2023] [Indexed: 04/05/2023]
Abstract
Therapeutic approaches providing effective medication for Alzheimer's disease (AD) patients after disease onset are urgently needed. Previous studies in AD mouse models and in humans suggested that physical exercise or changed lifestyle can delay AD-related synaptic and memory dysfunctions when treatment started in juvenile animals or in elderly humans before onset of disease symptoms. However, a pharmacological treatment that can reverse memory deficits in AD patients was thus far not identified. Importantly, AD disease-related dysfunctions have increasingly been associated with neuro-inflammatory mechanisms and searching for anti-inflammatory medication to treat AD seems promising. Like for other diseases, repurposing of FDA-approved drugs for treatment of AD is an ideally suited strategy to reduce the time to bring such medication into clinical practice. Of note, the sphingosine-1-phosphate analogue fingolimod (FTY720) was FDA-approved in 2010 for treatment of multiple sclerosis patients. It binds to the five different isoforms of Sphingosine-1-phosphate receptors (S1PRs) that are widely distributed across human organs. Interestingly, recent studies in five different mouse models of AD suggest that FTY720 treatment, even when starting after onset of AD symptoms, can reverse synaptic deficits and memory dysfunction in these AD mouse models. Furthermore, a very recent multi-omics study identified mutations in the sphingosine/ceramide pathway as a risk factor for sporadic AD, suggesting S1PRs as promising drug target in AD patients. Therefore, progressing with FDA-approved S1PR modulators into human clinical trials might pave the way for these potential disease modifying anti-AD drugs.
Collapse
Affiliation(s)
- Volkmar Leßmann
- Institute for Physiology, Medical Faculty, Otto-Von-Guericke-University, Leipziger Str. 44, 39120, Magdeburg, Germany.
- Center for Behavioral Brain Sciences, Magdeburg, Germany.
| | - Georgia-Ioanna Kartalou
- Institute for Physiology, Medical Faculty, Otto-Von-Guericke-University, Leipziger Str. 44, 39120, Magdeburg, Germany
- Institute of Neuro- and Sensory Physiology, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Thomas Endres
- Institute for Physiology, Medical Faculty, Otto-Von-Guericke-University, Leipziger Str. 44, 39120, Magdeburg, Germany
- Institute of Neuro- and Sensory Physiology, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
| | - Marc Pawlitzki
- Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Duesseldorf, Germany
| | - Kurt Gottmann
- Institute of Neuro- and Sensory Physiology, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany.
| |
Collapse
|
7
|
Senzaki K, Ochi H, Ochi M, Okada Y, Miura S, Ohyagi Y. Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod. eNeurologicalSci 2021; 23:100346. [PMID: 34041374 PMCID: PMC8142249 DOI: 10.1016/j.ensci.2021.100346] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 04/15/2021] [Accepted: 05/14/2021] [Indexed: 11/30/2022] Open
Affiliation(s)
- Kensuke Senzaki
- Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Japan
| | - Hirofumi Ochi
- Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Japan
| | - Masayuki Ochi
- Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Japan
| | - Yoko Okada
- Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Japan
| | - Shiroh Miura
- Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Japan
| | - Yasumasa Ohyagi
- Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Toon, Japan
| |
Collapse
|
8
|
Song JH, Kim GT, Park KH, Park WJ, Park TS. Bioactive Sphingolipids as Major Regulators of Coronary Artery Disease. Biomol Ther (Seoul) 2021; 29:373-383. [PMID: 33903284 PMCID: PMC8255146 DOI: 10.4062/biomolther.2020.218] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 01/04/2021] [Accepted: 01/06/2021] [Indexed: 12/31/2022] Open
Abstract
Atherosclerosis is the deposition of plaque in the main arteries. It is an inflammatory condition involving the accumulation of macrophages and various lipids (low-density lipoprotein [LDL] cholesterol, ceramide, S1P). Moreover, endothelial cells, macrophages, leukocytes, and smooth muscle cells are the major players in the atherogenic process. Sphingolipids are now emerging as important regulators in various pathophysiological processes, including the atherogenic process. Various sphingolipids exist, such as the ceramides, ceramide-1-phosphate, sphingosine, sphinganine, sphingosine-1-phosphate (S1P), sphingomyelin, and hundreds of glycosphingolipids. Among these, ceramides, glycosphingolipids, and S1P play important roles in the atherogenic processes. The atherosclerotic plaque consists of higher amounts of ceramide, glycosphingolipids, and sphingomyelin. The inhibition of the de novo ceramide biosynthesis reduces the development of atherosclerosis. S1P regulates atherogenesis via binding to the S1P receptor (S1PR). Among the five S1PRs (S1PR1-5), S1PR1 and S1PR3 mainly exert anti-atherosclerotic properties. This review mainly focuses on the effects of ceramide and S1P via the S1PR in the development of atherosclerosis. Moreover, it discusses the recent findings and potential therapeutic implications in atherosclerosis.
Collapse
Affiliation(s)
- Jae-Hwi Song
- Department of Life Science, Gachon University, Sungnam 13120, Republic of Korea
| | - Goon-Tae Kim
- Department of Life Science, Gachon University, Sungnam 13120, Republic of Korea
| | - Kyung-Ho Park
- Department of Nutrition, Hallym University, Chuncheon 24252, Republic of Korea
| | - Woo-Jae Park
- Department of Biochemistry, College of Medicine, Gachon University, Incheon 21999, Republic of Korea
| | - Tae-Sik Park
- Department of Life Science, Gachon University, Sungnam 13120, Republic of Korea
| |
Collapse
|
9
|
Hou H, Sun Y, Miao J, Gao M, Guo L, Song X. Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis. J Neuroimmunol 2021; 356:577583. [PMID: 33940233 DOI: 10.1016/j.jneuroim.2021.577583] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2020] [Revised: 04/20/2021] [Accepted: 04/21/2021] [Indexed: 02/06/2023]
Abstract
Sphingosine-1-phosphate receptor 1 (S1P1) plays an important role in autoimmune disease. Here, we evaluated whether ponesimod, an S1P1 modulator, affects inflammation in experimental autoimmune encephalomyelitis (EAE) and investigated Th1/Th2/Th17/Treg cell subsets. Ponesimod treatment ameliorated EAE and alleviated inflammatory infiltration. Compared with untreated EAE, ponesimod-treated mice had lower Th1 and Th17 cell numbers and higher Treg cell numbers; their IFN-γ, T-bet, IL-17, and RORγt levels as well as their pmTOR/mTOR ratio were diminished, while their TGF-β and Foxp3 levels were enhanced. These results suggest that ponesimod modulates the Th1/Th17/Treg balance and regulates the mTOR pathway.
Collapse
Affiliation(s)
- Huiqing Hou
- Department of Neurology, Key Laboratory of Hebei Neurology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China
| | - Yafei Sun
- Department of Neurology, Key Laboratory of Hebei Neurology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China
| | - Jun Miao
- Department of Dermatology, North China Petroleum Bureau General Hospital of Hebei Medical University, Renqiu 062552, Hebei, China
| | - Mengying Gao
- Emergency Department, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China
| | - Li Guo
- Department of Neurology, Key Laboratory of Hebei Neurology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China
| | - Xiujuan Song
- Department of Neurology, Key Laboratory of Hebei Neurology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, China.
| |
Collapse
|
10
|
Sukocheva OA, Furuya H, Ng ML, Friedemann M, Menschikowski M, Tarasov VV, Chubarev VN, Klochkov SG, Neganova ME, Mangoni AA, Aliev G, Bishayee A. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther 2020; 207:107464. [PMID: 31863815 DOI: 10.1016/j.pharmthera.2019.107464] [Citation(s) in RCA: 64] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 12/10/2019] [Indexed: 02/07/2023]
Abstract
Inflammatory gastrointestinal (GI) diseases and malignancies are associated with growing morbidity and cancer-related mortality worldwide. GI tumor and inflammatory cells contain activated sphingolipid-metabolizing enzymes, including sphingosine kinase 1 (SphK1) and SphK2, that generate sphingosine-1-phosphate (S1P), a highly bioactive compound. Many inflammatory responses, including lymphocyte trafficking, are directed by circulatory S1P, present in high concentrations in both the plasma and the lymph of cancer patients. High fat and sugar diet, disbalanced intestinal flora, and obesity have recently been linked to activation of inflammation and SphK/S1P/S1P receptor (S1PR) signaling in various GI pathologies, including cancer. SphK1 overexpression and activation facilitate and enhance the development and progression of esophageal, gastric, and colon cancers. SphK/S1P axis, a mediator of inflammation in the tumor microenvironment, has recently been defined as a target for the treatment of GI disease states, including inflammatory bowel disease and colitis. Several SphK1 inhibitors and S1PR antagonists have been developed as novel anti-inflammatory and anticancer agents. In this review, we analyze the mechanisms of SphK/S1P signaling in GI tissues and critically appraise recent studies on the role of SphK/S1P/S1PR in inflammatory GI disorders and cancers. The potential role of SphK/S1PR inhibitors in the prevention and treatment of inflammation-mediated GI diseases, including GI cancer, is also evaluated.
Collapse
Affiliation(s)
- Olga A Sukocheva
- Discipline of Health Sciences, College of Nursing and Health Sciences, Flinders University, Bedford Park, South Australia 5042, Australia
| | - Hideki Furuya
- Department of Surgery, Samuel Oschin Cancer Center Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
| | - Mei Li Ng
- Advanced Medical and Dental Institute, University Sains 13200 Kepala Batas, Pulau Pinang, Malaysia
| | - Markus Friedemann
- Institute of Clinical Chemistry and Laboratory Medicine, University Hospital `Carl Gustav Carus`, Technical University of Dresden, Dresden 01307, Germany
| | - Mario Menschikowski
- Institute of Clinical Chemistry and Laboratory Medicine, University Hospital `Carl Gustav Carus`, Technical University of Dresden, Dresden 01307, Germany
| | - Vadim V Tarasov
- Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia
| | - Vladimir N Chubarev
- Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia
| | - Sergey G Klochkov
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka 142432, Russia
| | - Margarita E Neganova
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka 142432, Russia
| | - Arduino A Mangoni
- Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Bedford Park, South Australia 5042, Australia
| | - Gjumrakch Aliev
- Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka 142432, Russia; GALLY International Research Institute, San Antonio, TX 78229, USA; Research Institute of Human Morphology, Moscow 117418, Russia
| | - Anupam Bishayee
- Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA.
| |
Collapse
|
11
|
Wang Z, Higashikawa K, Yasui H, Kuge Y, Ohno Y, Kihara A, Midori YA, Houkin K, Kawabori M. FTY720 Protects Against Ischemia-Reperfusion Injury by Preventing the Redistribution of Tight Junction Proteins and Decreases Inflammation in the Subacute Phase in an Experimental Stroke Model. Transl Stroke Res 2020; 11:1103-1116. [PMID: 32103462 PMCID: PMC7496052 DOI: 10.1007/s12975-020-00789-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Revised: 01/22/2020] [Accepted: 02/12/2020] [Indexed: 12/18/2022]
Abstract
Injury due to brain ischemia followed by reperfusion (I/R) may be an important therapeutic target in the era of thrombectomy. FTY720, a widely known sphingosine-1-phosphate receptor agonist, exerts various neuroprotective effects. The aim of this study was to examine the protective effect of FTY720 with respect to I/R injury, especially focusing on blood-brain barrier (BBB) protection and anti-inflammatory effects. Male rats were subjected to transient ischemia and administered vehicle or 0.5 or 1.5 mg/kg of FTY720 immediately before reperfusion. Positron emission tomography (PET) with [18F]DPA-714 was performed 2 and 9 days after the insult to serially monitor neuroinflammation. Bovine and rat brain microvascular endothelial cells (MVECs) were also subjected to oxygen-glucose deprivation (OGD) and reperfusion, and administered FTY720, phosphorylated-FTY720 (FTY720-P), or their inhibitor. FTY720 dose-dependently reduced cell death, the infarct size, cell death including apoptosis, and inflammation. It also ameliorated BBB disruption and neurological deficits compared to in the vehicle group. PET indicated that FTY720 significantly inhibited the worsening of inflammation in later stages. FTY720-P significantly prevented the intracellular redistribution of tight junction proteins but did not increase their mRNA expression. These results suggest that FTY720 can ameliorate I/R injury by protecting the BBB and regulating neuroinflammation.
Collapse
Affiliation(s)
- Zifeng Wang
- Department of Neurosurgery, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Kei Higashikawa
- Central Institutes of Isotope Science (Laboratory of Integrated Molecular Imaging, Department of Biomedical Imaging, Graduate School of Biomedical Science and Engineering), Hokkaido University, Sapporo, Hokkaido, Japan
| | - Hironobu Yasui
- Central Institutes of Isotope Science (Laboratory of Integrated Molecular Imaging, Department of Biomedical Imaging, Graduate School of Biomedical Science and Engineering), Hokkaido University, Sapporo, Hokkaido, Japan
| | - Yuji Kuge
- Central Institutes of Isotope Science (Laboratory of Integrated Molecular Imaging, Department of Biomedical Imaging, Graduate School of Biomedical Science and Engineering), Hokkaido University, Sapporo, Hokkaido, Japan
| | - Yusuke Ohno
- Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido, Japan
| | - Akio Kihara
- Laboratory of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido, Japan
| | - Yenari A Midori
- Department of Neurology, University of California, San Francisco and the San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA
| | - Kiyohiro Houkin
- Department of Neurosurgery, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
| | - Masahito Kawabori
- Department of Neurosurgery, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
| |
Collapse
|
12
|
Abstract
Cardiomyopathy is the leading cause of mortality worldwide. While the causes of cardiomyopathy continue to be elucidated, current evidence suggests that aberrant bioactive lipid signaling plays a crucial role as a component of cardiac pathophysiology. Sphingolipids have been implicated in the pathophysiology of cardiovascular disease, as they regulate numerous cellular processes that occur in primary and secondary cardiomyopathies. Experimental evidence gathered over the last few decades from both in vitro and in vivo model systems indicates that inhibitors of sphingolipid synthesis attenuate a variety of cardiomyopathic symptoms. In this review, we focus on various cardiomyopathies in which sphingolipids have been implicated and the potential therapeutic benefits that could be gained by targeting sphingolipid metabolism.
Collapse
Affiliation(s)
- Anna Kovilakath
- Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA
| | - L. Ashley Cowart
- Department of Biochemistry and Molecular Biology and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
- Hunter Holmes McGuire Veteran's Affairs Medical Center, Richmond, VA, USA
| |
Collapse
|
13
|
Sukocheva OA, Lukina E, McGowan E, Bishayee A. Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease. Adv Protein Chem Struct Biol 2020; 120:123-158. [PMID: 32085881 DOI: 10.1016/bs.apcsb.2019.11.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Morbidity of inflammatory gastrointestinal (GI) diseases continues to grow resulting in worsen quality of life and increased burden on public medical systems. Complex and heterogenous illnesses, inflammatory bowel diseases (IBDs) encompass several inflammation -associated pathologies including Crohn's disease and ulcerative colitis. IBD is often initiated by a complex interplay between host genetic and environmental factors, lifestyle and diet, and intestinal bacterial components. IBD inflammatory signature was linked to the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) signaling pathway that is currently targeted by IBD therapies. Sphingolipid signaling was identified as one of the key mediators and regulators of pro-inflammatory conditions, and, specifically, TNF-α related signaling. All GI tissues and circulating immune/blood cells contain activated sphingolipid-metabolizing enzymes, including sphingosine kinases (SphK1 and SphK2) that generate sphingosine-1-phosphate (S1P), a bioactive lipid and ligand for five G-protein coupled membrane S1P receptors (S1PRs). Numerous normal and pathogenic inflammatory responses are mediated by SphK/S1P/S1PRs signaling axis including lymphocyte trafficking and activation of cytokine signaling machinery. SphK1/S1P/S1PRs axis has recently been defined as a target for the treatment of GI diseases including IBD/colitis. Several SphK1 inhibitors and S1PRs antagonists have been developed as novel anti-inflammatory agents. In this review, we discuss the mechanisms of SphK/S1P signaling in inflammation-linked GI disorders. The potential role of SphK/S1PRs inhibitors in the prevention and treatment of IBD/colitis is critically evaluated.
Collapse
Affiliation(s)
- Olga A Sukocheva
- Discipline of Health Sciences, College of Nursing and Health Sciences, Flinders University, Bedford Park, SA, Australia
| | - Elena Lukina
- Discipline of Health Sciences, College of Nursing and Health Sciences, Flinders University, Bedford Park, SA, Australia
| | - Eileen McGowan
- School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia
| | - Anupam Bishayee
- Lake Erie College of Osteopathic Medicine, Bradenton, FL, United States
| |
Collapse
|
14
|
Kürtüncü M, Yılmaz V, Akçay Hİ, Türkoğlu R, Altunrende B, Çınar SA, Ulusoy C, Gündüz T, İçöz S, Kasap M, Çalışkan Z, Ötünç G, Eraksoy M, Tüzün E. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients. J Neuroimmunol 2019; 337:577065. [PMID: 31526917 DOI: 10.1016/j.jneuroim.2019.577065] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 09/07/2019] [Accepted: 09/10/2019] [Indexed: 10/26/2022]
Abstract
Fingolimod inhibits the egress of lymphocytes from lymphatic tissues and also directly affects their functions by modulation of the sphingosine-1-phosphate receptor 1 (S1P1). Our aim was to evaluate the impact of fingolimod on diverse CD4+ T cell subsets, and cytokines. Sixty-six relapsing remitting multiple sclerosis (RRMS) patients were treated with oral fingolimod (0.5 mg) for 6 months, and blood samples were collected at baseline, 3 months, and 6 months. Serum levels of seven cytokines and five chemokines were measured by multiplex immunoassay, and frequencies of peripheral blood mononuclear cell subsets were assessed by flow cytometry, and compared with those of 60 healthy controls. CCL2 (p = 0.039), and CCL5 (p = 0.001) levels were significantly higher in fingolimod-treated patients than healthy controls, whereas end-of-study serum levels of IL-6, IL-8, IL-17A, IL-22, IL-23, TNF-α, CXCL10, and CXCL13 were comparable to the baseline levels. Six months of fingolimod treatment reduced CD3+ T cell (mean ± standard deviation, 72.9% ± 5.5 vs. 60.1% ± 11.1, p < 0.001), CD4+ T cell (62.2% ± 8.5 vs. 24.6% ± 12.9, p < 0.001), CD4+CD25hi regulatory T cell (Treg) (3.4% ± 1.3 vs. 2.0% ± 1.4, p < 0.01), and CD19+ B cell (13.2% ± 5.8 vs. 5.3% ± 2.7, p < 0.001) frequencies, while CD8+ T cells (31.8% ± 7.8 vs. 57.8% ± 13.2, p < 0.001) were increased, and NK and NKT cells remained unchanged. The proportions of intracytoplasmic IL-4, IL-10, IFN-γ, and TNF-α-producing T cells were increased, whereas IL-17-producing cells remained relatively constant as measured by flow cytometry. Fingolimod appears to primarily diminish lymphocyte subsets involved in antigen presentation (CD19+ B and CD4+ T cells) rather than immune cells (CD8+ T, NK, and NKT cells) in charge of host defense against pathogens. In contrast, a relative increase is observed in pro- and anti-inflammatory cytokine-producing T helper subsets (IFN-γ, TNF-α, IL-4, and IL-10-producing CD4+ T cells), suggesting that effector T cells are suppressed to a lesser degree by S1P1 modulation.
Collapse
Affiliation(s)
- Murat Kürtüncü
- Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
| | - Vuslat Yılmaz
- Department of Neuroscience, Aziz Sancar Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Halil İbrahim Akçay
- Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Recai Türkoğlu
- Department of Neurology, Saglik Bilimleri University, Istanbul, Turkey
| | - Burcu Altunrende
- Department of Neurology, Faculty of Medicine, Istanbul Bilim University, Istanbul, Turkey
| | - Suzan Adın Çınar
- Department of Immunology, Aziz Sancar Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Canan Ulusoy
- Department of Neuroscience, Aziz Sancar Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| | - Tuncay Gündüz
- Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Sema İçöz
- Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | | | | | | | - Mefküre Eraksoy
- Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Erdem Tüzün
- Department of Neuroscience, Aziz Sancar Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey
| |
Collapse
|
15
|
Abstract
There is an ongoing, unmet need for effective therapies for Crohn's disease. Treatments for Crohn's disease continue to evolve from the traditional biologics to novel small molecules, with targeted mechanisms directed toward pathways that are dysregulated in Crohn's disease. There are multiple emerging mechanisms of action, including Janus kinase inhibition, Smad7 inhibition, and sphingosine-1-phosphate receptor modulators, that are administered as oral medications, and small molecules represent the next generation of therapies for Crohn's disease.
Collapse
Affiliation(s)
- Brigid S. Boland
- Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, University of California San Diego, USA,Corresponding Author: Brigid S. Boland Address: ACTRI, 9452 Medical Center Drive, La Jolla, CA 92093, USA,
| | - Séverine Vermeire
- Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
| |
Collapse
|
16
|
Arish M, Alaidarous M, Ali R, Akhter Y, Rub A. Implication of sphingosine-1-phosphate signaling in diseases: molecular mechanism and therapeutic strategies. J Recept Signal Transduct Res 2017; 37:437-446. [PMID: 28758826 DOI: 10.1080/10799893.2017.1358282] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Sphingosine-1-phosphate signaling is emerging as a critical regulator of cellular processes that is initiated by the intracellular production of bioactive lipid molecule, sphingosine-1-phosphate. Binding of sphingosine-1-phosphate to its extracellular receptors activates diverse downstream signaling that play a critical role in governing physiological processes. Increasing evidence suggests that this signaling pathway often gets impaired during pathophysiological and diseased conditions and hence manipulation of this signaling pathway may be beneficial in providing treatment. In this review, we summarized the recent findings of S1P signaling pathway and the versatile role of the participating candidates in context with several disease conditions. Finally, we discussed its possible role as a novel drug target in different diseases.
Collapse
Affiliation(s)
- Mohd Arish
- a Infection and Immunity Lab, Department of Biotechnology , Jamia Millia Islamia (A Central University) , New Delhi , India
| | - Mohammed Alaidarous
- b Department of Medical Laboratory Sciences, College of Applied Medical Sciences , Majmaah University , Al Majmaah , Saudi Arabia
| | - Rahat Ali
- a Infection and Immunity Lab, Department of Biotechnology , Jamia Millia Islamia (A Central University) , New Delhi , India
| | - Yusuf Akhter
- c Centre for Computational Biology & Bioinformatics, School of Life Sciences , Central University of Himachal Pradesh , Shahpur, Kangra , India
| | - Abdur Rub
- a Infection and Immunity Lab, Department of Biotechnology , Jamia Millia Islamia (A Central University) , New Delhi , India.,b Department of Medical Laboratory Sciences, College of Applied Medical Sciences , Majmaah University , Al Majmaah , Saudi Arabia
| |
Collapse
|
17
|
Abstract
Local anatomy of lymphoid tissues during infection has emerged as a critical regulator of immunity; thus, studying the cellular choreography in the context of an intact tissue environment in situ is crucial. Following an infection, the local pathogen-specific T cell migration and the subsequent egress of effector T cells from the draining lymph nodes are important and complex biological processes. The mechanisms that regulate this complex process can now be investigated by directly visualizing T cell dynamics in vivo using intravital two-photon (2P) microscopy. In addition, static whole-mount imaging technique can provide us with a comprehensive assessment of global changes in the distribution of cellular populations within an intact tissue. Thus, in this chapter, we detail methods to visualize the migration and egress of endogenous antigen-specific CD8 T cells following viral infection using two methods-intravital 2P microscopy and multicolor whole-mount in situ tetramer staining.
Collapse
|
18
|
Harrington PE, Croghan MD, Fotsch C, Frohn M, Lanman BA, Pennington LD, Pickrell AJ, Reed AB, Sham KKC, Tasker A, Arnett HA, Fiorino M, Lee MR, McElvain M, Morrison HG, Xu H, Xu Y, Zhang X, Wong M, Cee VJ. Optimization of a Potent, Orally Active S1P1 Agonist Containing a Quinolinone Core. ACS Med Chem Lett 2012; 3:74-8. [PMID: 24900374 DOI: 10.1021/ml200252b] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2011] [Accepted: 11/23/2011] [Indexed: 01/18/2023] Open
Abstract
The optimization of a series of S1P1 agonists with limited activity against S1P3 is reported. A polar headgroup was used to improve the physicochemical and pharmacokinetic parameters of lead quinolinone 6. When dosed orally at 1 and 3 mg/kg, the azahydroxymethyl analogue 22 achieved statistically significant lowering of circulating blood lymphocytes 24 h postdose. In rats, a dose-proportional increase in exposure was measured when 22 was dosed orally at 2 and 100 mg/kg.
Collapse
Affiliation(s)
- Paul E. Harrington
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michael D. Croghan
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Christopher Fotsch
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Mike Frohn
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Brian A. Lanman
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Lewis D. Pennington
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Alexander J. Pickrell
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Anthony B. Reed
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Kelvin K. C. Sham
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Andrew Tasker
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Heather A. Arnett
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michael Fiorino
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Matthew R. Lee
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Michele McElvain
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Henry G. Morrison
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Han Xu
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Yang Xu
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Xuxia Zhang
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Min Wong
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Victor J. Cee
- Chemistry
Research and Discovery, ‡Inflammation Research, §Molecular Structure, ∥HTS and Molecular Pharmacology, ⊥Pharmaceutics, and #Pharmacokinetics and
Drug Metabolism, Amgen, One
Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| |
Collapse
|
19
|
Lanman BA, Cee VJ, Cheruku S, Frohn M, Golden J, Lin J, Lobera M, Marantz Y, Muller KM, Neira SC, Pickrell AJ, Rivenzon-Segal D, Schutz N, Sharadendu A, Yu X, Zhang Z, Buys J, Fiorino M, Gore A, Horner M, Itano A, McElvain M, Middleton S, Schrag M, Vargas HM, Xu H, Xu Y, Zhang X, Siu J, Bürli RW. Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1). ACS Med Chem Lett 2011; 2:102-6. [PMID: 24900287 PMCID: PMC4018108 DOI: 10.1021/ml100228m] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Accepted: 11/03/2010] [Indexed: 01/31/2023] Open
Abstract
Optimization of a benzofuranyl S1P1 agonist lead compound (3) led to the discovery of 1-(3-fluoro-4-(5-(2-fluorobenzyl)benzo[d]thiazol-2-yl)benzyl)azetidine-3-carboxylic acid (14), a potent S1P1 agonist with minimal activity at S1P3. Dosed orally at 0.3 mg/kg, 14 significantly reduced blood lymphocyte counts 24 h postdose and attenuated a delayed type hypersensitivity (DTH) response to antigen challenge.
Collapse
Affiliation(s)
- Brian A. Lanman
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Victor J. Cee
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Srinivasa
R. Cheruku
- EPIX Pharmaceuticals Inc., 167
Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481,
United States
| | - Mike Frohn
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Jennifer Golden
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Jian Lin
- EPIX Pharmaceuticals Inc., 167
Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481,
United States
| | - Mercedes Lobera
- EPIX Pharmaceuticals Inc., 167
Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481,
United States
| | - Yael Marantz
- EPIX Pharmaceuticals Inc., 167
Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481,
United States
| | - Kristine M. Muller
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Susana C. Neira
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | | | - Dalia Rivenzon-Segal
- EPIX Pharmaceuticals Inc., 167
Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481,
United States
| | - Nili Schutz
- EPIX Pharmaceuticals Inc., 167
Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481,
United States
| | - Anurag Sharadendu
- EPIX Pharmaceuticals Inc., 167
Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481,
United States
| | - Xiang Yu
- EPIX Pharmaceuticals Inc., 167
Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481,
United States
| | - Zhaoda Zhang
- EPIX Pharmaceuticals Inc., 167
Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481,
United States
| | - Janet Buys
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Mike Fiorino
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Anu Gore
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Michelle Horner
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Andrea Itano
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Michele McElvain
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Scot Middleton
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Michael Schrag
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Hugo M. Vargas
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Han Xu
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Yang Xu
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Xuxia Zhang
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Jerry Siu
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Roland W. Bürli
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|
20
|
Cee VJ, Frohn M, Lanman BA, Golden J, Muller K, Neira S, Pickrell A, Arnett H, Buys J, Gore A, Fiorino M, Horner M, Itano A, Lee MR, McElvain M, Middleton S, Schrag M, Rivenzon-Segal D, Vargas HM, Xu H, Xu Y, Zhang X, Siu J, Wong M, Bürli RW. Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5. ACS Med Chem Lett 2011; 2:107-12. [PMID: 24900288 DOI: 10.1021/ml100306h] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Accepted: 12/21/2010] [Indexed: 02/02/2023] Open
Abstract
The optimization of a series of thiazolopyridine S1P1 agonists with limited activity at the S1P3 receptor is reported. These efforts resulted in the discovery of 1-(3-fluoro-4-(5-(1-phenylcyclopropyl)thiazolo-[5,4-b]pyridin-2-yl)benzyl)azetidine-3-carboxylic acid (5d, AMG 369), a potent dual S1P1/S1P5 agonist with limited activity at S1P3 and no activity at S1P2/S1P4. Dosed orally at 0.1 mg/kg, 5d is shown to reduce blood lymphocyte counts 24 h postdose and delay the onset and reduce the severity of experimental autoimmune encephalomyelitis in rat.
Collapse
Affiliation(s)
- Victor J. Cee
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Mike Frohn
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Brian A. Lanman
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Jennifer Golden
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Kristine Muller
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Susana Neira
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Alex Pickrell
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Heather Arnett
- Amgen Inc., 1201 Amgen Court West, Seattle, Washington 98119, United States
| | - Janet Buys
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Anu Gore
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Mike Fiorino
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Michelle Horner
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Andrea Itano
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Matt R. Lee
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Michele McElvain
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Scot Middleton
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Michael Schrag
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Dalia Rivenzon-Segal
- EPIX Pharmaceuticals Inc., 167 Worcester Street, Suite 201, Wellesley Hills, Massachusetts 02481, United States
| | - Hugo M. Vargas
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Han Xu
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Yang Xu
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Xuxia Zhang
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Jerry Siu
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Min Wong
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| | - Roland W. Bürli
- Amgen Inc., One Amgen Center
Drive, Thousand Oaks, California 91320, United States
| |
Collapse
|